Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$25.50
-2.4%
$25.18
$2.76
$30.60
$3.32B-0.311.18 million shs560,541 shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$222.63
-0.2%
$172.69
$96.09
$234.29
$11.48B0.59913,522 shs559,805 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$26.21
+14.0%
$23.85
$10.75
$27.72
$11.43B1.694.42 million shs12.36 million shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$13.46
+1.5%
$13.75
$12.77
$16.17
$11.07B0.272.56 million shs4.34 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
-2.41%+11.40%+16.23%-3.19%+485.80%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-0.19%+21.03%+31.16%+23.11%+98.49%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+13.70%+20.14%+14.91%+7.93%+174.99%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
+1.48%-2.22%+2.35%-3.68%-0.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$25.50
-2.4%
$25.18
$2.76
$30.60
$3.32B-0.311.18 million shs560,541 shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$222.63
-0.2%
$172.69
$96.09
$234.29
$11.48B0.59913,522 shs559,805 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$26.21
+14.0%
$23.85
$10.75
$27.72
$11.43B1.694.42 million shs12.36 million shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$13.46
+1.5%
$13.75
$12.77
$16.17
$11.07B0.272.56 million shs4.34 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
-2.41%+11.40%+16.23%-3.19%+485.80%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-0.19%+21.03%+31.16%+23.11%+98.49%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+13.70%+20.14%+14.91%+7.93%+174.99%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
+1.48%-2.22%+2.35%-3.68%-0.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alumis Inc. stock logo
ALMS
Alumis
2.92
Moderate Buy$38.6051.37% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.90
Moderate Buy$251.2612.86% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$27.906.46% Upside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00
Hold$16.9025.55% Upside

Current Analyst Ratings Breakdown

Latest ALMS, RDY, ELAN, and AXSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Set Price Target$280.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$225.00 ➝ $255.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$242.00 ➝ $302.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$270.00 ➝ $290.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetEqual Weight$217.00 ➝ $242.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOverweight$225.00 ➝ $255.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$228.00 ➝ $310.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$241.00 ➝ $246.00
5/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Set Price Target$280.00
5/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$245.00 ➝ $260.00
4/27/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UpgradeSell (D)Sell (D+)
(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alumis Inc. stock logo
ALMS
Alumis
$24.05M134.87N/AN/A$2.88 per share8.85
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M17.94N/AN/A$1.06 per share210.03
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.76$2.64 per share9.91$13.18 per share1.99
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.81B2.95$1.05 per share12.84$4.73 per share2.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alumis Inc. stock logo
ALMS
Alumis
-$243.32M-$3.06N/AN/AN/A-1,011.75%-116.97%-88.43%5/13/2026 (Estimated)
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.69N/A40.04N/A-26.59%-267.16%-28.53%N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.48N/A22.402.93-4.92%7.16%3.53%N/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$663M$0.7717.4823.2120.6016.41%15.89%10.73%5/12/2026 (Estimated)

Latest ALMS, RDY, ELAN, and AXSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Alumis Inc. stock logo
ALMS
Alumis
-$0.79N/AN/AN/A$2.49 millionN/A
5/12/2026Q4 25/26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.09N/AN/AN/A$886.58 millionN/A
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/4/2026Q1 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million
3/19/2026Q4 2025
Alumis Inc. stock logo
ALMS
Alumis
-$0.90-$0.95-$0.05-$0.94$2.75 million$1.93 million
2/24/2026Q4 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.11$0.13+$0.02-$0.56$1.09 billion$1.14 billion
2/23/2026Q4 2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.70-$0.56+$0.14-$0.56$191.33 million$196.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.070.52%+9.86%9.09%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alumis Inc. stock logo
ALMS
Alumis
N/A
4.34
4.34
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.27
1.39
1.48
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.17
1.08
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.03
1.88
1.38

Institutional Ownership

CompanyInstitutional Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%

Insider Ownership

CompanyInsider Ownership
Alumis Inc. stock logo
ALMS
Alumis
40.70%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alumis Inc. stock logo
ALMS
Alumis
N/A127.20 million75.43 millionN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38051.46 million40.84 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400497.17 million491.50 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,811834.65 million817.96 millionOptionable

Recent News About These Companies

Doctor Reddy's: Fiscal Q3 Earnings Snapshot
Dr. Reddy's Laboratories Ltd (RDY) Stock Forecasts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alumis stock logo

Alumis NASDAQ:ALMS

$25.50 -0.63 (-2.41%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$25.40 -0.10 (-0.40%)
As of 07:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$222.63 -0.43 (-0.19%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$220.42 -2.21 (-0.99%)
As of 07:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$26.21 +3.22 (+13.99%)
Closing price 05/6/2026 03:59 PM Eastern
Extended Trading
$26.16 -0.05 (-0.20%)
As of 07:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$13.46 +0.20 (+1.52%)
Closing price 05/6/2026 03:59 PM Eastern
Extended Trading
$13.60 +0.14 (+1.00%)
As of 05:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.